drugset
drugset / Trial / NCT03876197

Mesenchymal Stem Cells for Radiation-induced Xerostomia

NCT03876197 ↗

Phase 1/2 Unknown 30 enrolled Rigshospitalet, Denmark
RandomizedParallel-groupTriple-blindOther

Summary

A prospective study for long-term follow-up (LTFU) to evaluate safety and efficacy in subjects who participated in the Phase 1/2 randomized placebo-controlled trial MESRIX.

Timeline

Start
2020-08-01
Primary completion
2022-12-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous adipose-derived mesenchymal stem/stromal cells Cell therapy — Other

Indications

radiation-induced disorder